Inspire Medical Systems (NYSE:INSP) has earned an average recommendation of “Hold” from the six analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $73.50.
Several equities analysts have commented on INSP shares. Zacks Investment Research lowered shares of Inspire Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, January 4th. Berenberg Bank upgraded shares of Inspire Medical Systems from a “sell” rating to a “hold” rating and increased their price objective for the company from $46.00 to $51.00 in a research report on Wednesday, November 6th. ValuEngine lowered shares of Inspire Medical Systems from a “hold” rating to a “sell” rating in a report on Friday, January 3rd. Dougherty & Co set a $78.00 target price on shares of Inspire Medical Systems and gave the stock a “buy” rating in a report on Friday, September 27th. Finally, Wells Fargo & Co raised their target price on shares of Inspire Medical Systems from $70.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday.
Shares of INSP stock traded up $1.09 during trading on Thursday, hitting $82.34. The company had a trading volume of 1,285 shares, compared to its average volume of 184,472. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.05 and a current ratio of 13.42. The firm has a market capitalization of $1.93 billion, a P/E ratio of -54.93 and a beta of 1.26. The stock’s 50-day moving average price is $74.00 and its 200 day moving average price is $66.09. Inspire Medical Systems has a one year low of $46.00 and a one year high of $82.15.
Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.09. The business had revenue of $20.86 million during the quarter, compared to the consensus estimate of $19.15 million. Inspire Medical Systems had a negative return on equity of 18.67% and a negative net margin of 40.36%. Inspire Medical Systems’s quarterly revenue was up 59.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.22) earnings per share. On average, research analysts anticipate that Inspire Medical Systems will post -1.46 earnings per share for the current fiscal year.
In related news, Director Jerry C. Griffin sold 10,000 shares of Inspire Medical Systems stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $71.21, for a total transaction of $712,100.00. Following the completion of the sale, the director now owns 53,412 shares in the company, valued at approximately $3,803,468.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Timothy P. Herbert sold 9,832 shares of Inspire Medical Systems stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $80.10, for a total transaction of $787,543.20. The disclosure for this sale can be found here. Insiders sold a total of 140,709 shares of company stock valued at $9,609,962 in the last 90 days. Company insiders own 12.10% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in INSP. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Inspire Medical Systems by 293.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 637 shares of the company’s stock valued at $39,000 after acquiring an additional 475 shares in the last quarter. Evoke Wealth LLC bought a new position in Inspire Medical Systems during the third quarter worth about $39,000. Marshall Wace North America L.P. bought a new position in Inspire Medical Systems during the first quarter worth about $45,000. Royal Bank of Canada lifted its holdings in Inspire Medical Systems by 593.3% during the second quarter. Royal Bank of Canada now owns 1,040 shares of the company’s stock worth $63,000 after acquiring an additional 890 shares in the last quarter. Finally, FinTrust Capital Advisors LLC lifted its holdings in Inspire Medical Systems by 250.0% during the third quarter. FinTrust Capital Advisors LLC now owns 2,100 shares of the company’s stock worth $129,000 after acquiring an additional 1,500 shares in the last quarter. Institutional investors own 89.69% of the company’s stock.
About Inspire Medical Systems
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Recommended Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.